Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control Study

Table 1

Patient characteristics and medical conditions.

Patient characteristic/medical condition (full analysis set)	Oxycodone (N = 33)	Morphine (N = 32)	value
Sex, male, n (%)	21 (63.6)	22 (68.8)	0.663
Age, mean ± SD, years	66.6 ± 9.1	64.1 ± 13.0	0.379^†
Age distribution, n (%)
19–39 years, n (%)	0 (0)	2 (6.3)	0.516^§
40–49 years, n (%)	1 (3.0)	2 (6.3)
50–59 years, n (%)	5 (15.2)	6 (18.7)
≥60 years, n (%)	27 (81.8)	22 (68.7)
Weight, mean ± SD, kg	58.9 ± 10.1	59.2 ± 12.2	0.925^†
Cancer duration, median (range), months	7.3 (0.1–72.0)	14.5 (0.1–149.0)	0.401^‡
<1 year, n (%)	20 (62.5)	14 (43.7)	0.392^§
≥1 to <5 years, n (%)	10 (31.2)	14 (43.7)
≥5 years, n (%)	2 (6.3)	4 (12.6)	—
Unknown	1	—	—
Cancer type
Pancreatic cancer	8 (24.2)	3 (9.4)	0.042^§
Gastric cancer	7 (21.2)	6 (18.8)	—
Gall bladder/biliary tract cancer	3 (9.1)	0 (0)	—
Lung cancer	2 (6.1)	5 (15.6)	—
Liver cancer	2 (6.1)	0 (0)	—
Breast cancer	2 (6.1)	0 (0)	—
Colorectal cancer	1 (3.0)	5 (15.6)	—
Other cancers	8 (24.2)	13 (40.6)	—
Cancer stage^††
I	0 (0)	0 (0)	0.432^§
II	2 (6.1)	0 (0)	—
III	4 (12.1)	2 (6.5)	—
IV	27 (81.8)	29 (93.5)	—
Unknown	—	1^††	—
Concurrent illnesses, n (%)	28 (84.5)	26 (81.3)	0.699
Had chemotherapy 14 days prior to screening till end of study, n (%)	14 (42.4)	18 (56.3)	0.265
Prior medication excluding anticancer therapy	32 (97.0)	31 (96.9)	>0.999^§

χ²-test; ^†2-sample t-test; ^§Fisher’s exact test; ^‡Wilcoxon rank sum test; Duration of cancer history (months) = (initiation date of study treatment − date of cancer diagnosis)/30; oxycodone group: 1 subject with unknown cancer duration was excluded; ^††morphine group: 1 subject with unknown cancer stage was excluded.